Navneet Puri, PhD
Advertisement
Articles by Navneet Puri, PhD
A new ophthalmic-only pharma company was formed when Nevakar spun off its pipeline of ocular drugs.
Advertisement
Latest Updated Articles
Pipeline: Presbyopia, night vision disturbance up next for VylumaPublished: July 24th 2021 | Updated:
First Vyluma product tackles pediatric myopiaPublished: July 23rd 2021 | Updated:
Nevakar spins off ophthalmic-only company VylumaPublished: June 1st 2021 | Updated:
- Vyluma pipeline focuses on refractive error
Published: July 22nd 2021 | Updated:
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Noninvasive LED light therapy shows long-term safety in early cataract follow-up
2
FDA approves Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for presbyopia
3
When Mites Meet Their Match: Empowering Patients With Targeted Treatment for Demodex Blepharitis
4
MRI study links glymphatic system dysfunction to idiopathic intracranial hypertension
5